© 2021 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
March 12, 2021
Yi-Bin Chen, MD, comments on the need for improvements in patient assessment tools, measurements of response, and therapeutic agents for the management of acute GvHD in the future.
Yi-Bin Chen, MD, considers potential treatment options for steroid-refractory aGvHD and examines the results of the phase 3 REACH2 study of ruxolitinib.
Yi-Bin Chen, MD, discusses diagnostic criteria and measurements of response as they relate to the case of a 50-year-old woman with steroid-refractory acute GvHD.
Yi-Bin Chen, MD, defines acute graft-versus-host disease (aGvHD) as a complication of allogeneic transplant, discusses the clinical risk factors, and reviews prophylactic treatment options.